NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase

Compound: 6-shogaol

TargetsGene NameGene IDCancerCell LinesIC50ED50EC50GI50RemarkReferences
IL8interleukin 83576Ovarian CarcinomaES-2----Treatment with 6-shogaol resulted in significant inhibition of IL-8 production in the ES-2 cell lines.18096028
IL8interleukin 83576Ovarian CancerSK-OV-3----Treatment with 6-shogaol resulted in significant inhibition of IL-8 production in the SKOV3 cell lines.18096028
MMP9matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)4318HepatomaHep-3B----The activity of MMP-9 was suppressed in a dose-dependent manner, but the MMP-2 activity was not significantly changed when HepG2 and Hep3B cells were treated with 6-shogaol (1, 2.5, 5, and 10 µM),respectively. The inhibitory effect on MMP-9 in hepatoma cells by 6-shogaol may be through the regulation of both uPA and TIMP-1. Analysis with semi-quantitative reverse transcription-PCR showed that the regulation of MMP-9 by 6-shogaol .20521273
MMP9matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)4318HepatomaHep G2----The activity of MMP-9 was suppressed in a dose-dependent manner, but the MMP-2 activity was not significantly changed when HepG2 and Hep3B cells were treated with 6-shogaol (1, 2.5, 5, and 10 µM),respectively. The inhibitory effect on MMP-9 in hepatoma cells by 6-shogaol may be through the regulation of both uPA and TIMP-1. Analysis with semi-quantitative reverse transcription-PCR showed that the regulation of MMP-9 by 6-shogaol .20521273
NFKB1nuclear factor of kappa light polypeptide gene enhancer in B-cells 14790Ovarian CancerSK-OV-3----treatment with 6-shogaol extract resulted in a significant inhibition of NF-kappaB activation in SKOV3 cell lines.18096028
NFKB1nuclear factor of kappa light polypeptide gene enhancer in B-cells 14790Ovarian CancerCaOV3----treatment with 6-shogaol resulted in a significant inhibition of NF-kappaB activation in CaOV3 cell line.18096028
PLAUplasminogen activator, urokinase5328HepatomaHep-3B----The physiological activity of MMP-9 is significantly related to the activity of uPA and TIMPs. uPA activity was not detectable in HepG2 cells with or without PMA induction, but it dose-dependently decreased in Hep3B cells after incubation with 6-shogaol for 24 h.20521273
PLAUplasminogen activator, urokinase5328HepatomaHep G2----The physiological activity of MMP-9 is significantly related to the activity of uPA and TIMPs. uPA activity was not detectable in HepG2 cells with or without PMA induction, but it dose-dependently decreased in Hep3B cells after incubation with 6-shogaol for 24 h.20521273
TIMP1TIMP metallopeptidase inhibitor 17076HepatomaHep-3B----The physiological activity of MMP-9 is significantly related to the activity of uPA and TIMPs. The protein level of TIMP-1 in HepG2 and Hep3B cells was increased in a dose-dependent manner along with a gradual increase in the concentrations of 6-shogaol used for 24 h treatment. Regulation of TIMP-1 by 6-shogaol in Hep3B cells may on the transcriptional leve.20521273
TIMP1TIMP metallopeptidase inhibitor 17076HepatomaHep G2----The physiological activity of MMP-9 is significantly related to the activity of uPA and TIMPs. The protein level of TIMP-1 in HepG2 and Hep3B cells was increased in a dose-dependent manner along with a gradual increase in the concentrations of 6-shogaol used for 24 h treatment. Regulation of TIMP-1 by 6-shogaol in Hep3B cells may on the transcriptional leve.20521273
VEGFAvascular endothelial growth factor A7422Ovarian CancerA-2780----6-shogaol treatment resulted in inhibition of VEGF secrettion. Inhibition of VEGF secretion was most evident in the ES-2 cell line (p = .007), as compared to the other cell lines tested (p = .19, .18, and .07 for A2780, CaOV3, andSKOV3 respectively).18096028
VEGFAvascular endothelial growth factor A7422Ovarian CancerCaOV3----6-shogaol treatment resulted in inhibition of VEGF secrettion. Inhibition of VEGF secretion was most evident in the ES-2 cell line (p = .007), as compared to the other cell lines tested (p = .19, .18, and .07 for A2780, CaOV3, andSKOV3 respectively).18096028
VEGFAvascular endothelial growth factor A7422Ovarian CancerSK-OV-3----6-shogaol treatment resulted in inhibition of VEGF secrettion. Inhibition of VEGF secretion was most evident in the ES-2 cell line (p = .007), as compared to the other cell lines tested (p = .19, .18, and .07 for A2780, CaOV3, andSKOV3 respectively).18096028
VEGFAvascular endothelial growth factor A7422Ovarian CarcinomaES-2----6-shogaol treatment resulted in inhibition of VEGF secrettion. Inhibition of VEGF secretion was most evident in the ES-2 cell line (p = .007), as compared to the other cell lines tested (p = .19, .18, and .07 for A2780, CaOV3, andSKOV3 respectively).18096028

 






Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.